LakeShore Biopharma Co., Ltd. (LSB)
(Delayed Data from NSDQ)
$0.73 USD
-0.09 (-10.98%)
Updated Aug 1, 2025 03:52 PM ET
After-Market: $0.71 -0.02 (-2.74%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
LSB 0.73 -0.09(-10.98%)
Will LSB be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for LSB based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for LSB
Catalent (CTLT) Tops Q4 Earnings and Revenue Estimates
Sol-Gel Technologies Ltd. (SLGL) Surpasses Q2 Earnings and Revenue Estimates
LSB: What are Zacks experts saying now?
Zacks Private Portfolio Services
Invivyd, Inc. (IVVD) Reports Q2 Loss, Lags Revenue Estimates
Roivant Sciences Ltd. (ROIV) Reports Q1 Loss, Tops Revenue Estimates
Other News for LSB
LakeShore Biopharma GAAP EPS of -RMB5.22, revenue of RMB615M
LakeShore Biopharma Announces Fiscal Year 2025 Financial Results | LSB Stock News
12 Health Care Stocks Moving In Tuesday's After-Market Session
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Why AES Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket